Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

COVID-19: FDA Revokes Its Umbrella EUA For Infusion Pumps And Their Accessories

The revocation was made to “protect the public health,” the agency’s chief scientist says in letter

Executive Summary

The US agency has revoked an umbrella emergency use authorization for infusion pumps and their accessories that it issued in mid-May.

You may also be interested in...



US Government Awards $481M To Help Cue Health Expand COVID-19 Test Production

Cue’s point-of-care molecular test earned an FDA emergency use authorization in June.

COVID-19: FDA Schedules More Virtual Town Halls For November And December

The US agency has announced four more webinars aimed at labs and manufacturers that are (or have) developed diagnostic tests for the novel coronavirus.

Ventilators, Infusion Pumps, PPE, And More: 96 Devices Make FDA’s Critical Medical Products List

The US FDA’s list of essential products for use during infectious diseases outbreaks and other public health threats comes almost three months after President Trump signed an executive order directing the agency to develop one.

Topics

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel